The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cheers O20.
Sorry cant post full content but sure you can google
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2020
Commission File Number: 001-38452
Mereo BioPharma
On March 4, 2020, the U.S. Securities and Exchange Commission (the “SEC”) issued an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. On March 25, 2020, the order was modified and superseded by a new SEC order (Release No. 34-88465), which provides conditional relief to public companies that are unable to timely comply with their filing obligations as a result of the novel coronavirus (“COVID-19”) outbreak (the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements of Exchange Act Section 13(a) or 15(d), and any person required to make any filings with respect to such registrant, is exempt from any requirement to file or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations 13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, if certain conditions are satisfied.
Mereo BioPharma Group plc (the “Company”) will be relying on the SEC Order to delay the filing of its Annual Report on Form 20-F for the year ended December 31, 2019 (the “Report”) due to circumstances related to COVID-19, which include disruptions to operations in terms of travel and limited access to the Company’s facilities resulting in an impact to staff’s ability to carry out some of their usual work. Potential investors and business partners also face increased challenges to complete the processes necessary to move ahead with an investment or partnership decision because of COVID-19’s impact on the business of potential investors or partners and their ability to complete the diligence process in a COVID-19 environment alongside a broader dynamic of highly volatile equity markets which are also adversely affecting this process. Notwithstanding the foregoing, the Company plans to file the Report no later than June 15, 2020 (which is 45 days from the Report’s original filing deadline of April 30, 2020).
In light of the current COVID-19 pandemic, the Company will be including the following Risk Factor in its Report:
The COVID-19 pandemic or any other similar pandemic may materially impact our business including our ability to obtain further financial investment and planned clinical developments.
The outbreak of COVID-19 has developed into a global pandemic, spreading to most regions of the world including the United States and the United Kingdom and to locations where we have facilities or ongoing clinica
Truff. It’s available on MREO listing. Here is The full Form 6 K
Hi OAPK20, still can`t find rns, I used to trade nasdaq many years
ago, nice simple site, easy to use, now full of ads practically unusable,
what site do you use for American stocks?
Dual listing so best to check releases both sides of the pond.
28th April - MREO.
Mereo BioPharma Group plc Intends to Rely on SEC Relief and Delay Filing of its 2019 Annual Report on Form 20-F
On March 4, 2020, the U.S. Securities and Exchange Commission (the “SEC”) issued an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. On March 25, 2020, the order was modified and superseded by a new SEC order (Release No. 34-88465), which provides conditional relief to public companies that are unable to timely comply with their filing obligations as a result of the novel coronavirus (“COVID-19”) outbreak (the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements of Exchange Act Section 13(a) or 15(d), and any person required to make any filings with respect to such registrant, is exempt from any requirement to file or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations 13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, if certain conditions are satisfied.
Mereo BioPharma Group plc (the “Company”) will be relying on the SEC Order to delay the filing of its Annual Report on Form 20-F for the year ended December 31, 2019 (the “Report”) due to circumstances related to COVID-19, which include disruptions to operations in terms of travel and limited access to the Company’s facilities resulting in an impact to staff’s ability to carry out some of their usual work. Potential investors and business partners also face increased challenges to complete the processes necessary to move ahead with an investment or partnership decision because of COVID-19’s impact on the business of potential investors or partners and their ability to complete the diligence process in a COVID-19 environment alongside a broader dynamic of highly volatile equity markets which are also adversely affecting this process. Notwithstanding the foregoing, the Company plans to file the Report no later than June 15, 2020 (which is 45 days from the Report’s original filing deadline of April 30, 2020).
28th April - MREO.
Mereo BioPharma Group plc Intends to Rely on SEC Relief and Delay Filing of its 2019 Annual Report on Form 20-F
On March 4, 2020, the U.S. Securities and Exchange Commission (the “SEC”) issued an order under Section 36 (Release No. 34-88318) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), granting exemptions from specified provisions of the Exchange Act and certain rules thereunder. On March 25, 2020, the order was modified and superseded by a new SEC order (Release No. 34-88465), which provides conditional relief to public companies that are unable to timely comply with their filing obligations as a result of the novel coronavirus (“COVID-19”) outbreak (the “SEC Order”). The SEC Order provides that a registrant subject to the reporting requirements of Exchange Act Section 13(a) or 15(d), and any person required to make any filings with respect to such registrant, is exempt from any requirement to file or furnish materials with the Commission under Exchange Act Sections 13(a), 13(f), 13(g), 14(a), 14(c), 14(f), 15(d) and Regulations 13A, Regulation 13D-G (except for those provisions mandating the filing of Schedule 13D or amendments to Schedule 13D), 14A, 14C and 15D, and Exchange Act Rules 13f-1, and 14f-1, as applicable, if certain conditions are satisfied.
Mereo BioPharma Group plc (the “Company”) will be relying on the SEC Order to delay the filing of its Annual Report on Form 20-F for the year ended December 31, 2019 (the “Report”) due to circumstances related to COVID-19, which include disruptions to operations in terms of travel and limited access to the Company’s facilities resulting in an impact to staff’s ability to carry out some of their usual work. Potential investors and business partners also face increased challenges to complete the processes necessary to move ahead with an investment or partnership decision because of COVID-19’s impact on the business of potential investors or partners and their ability to complete the diligence process in a COVID-19 environment alongside a broader dynamic of highly volatile equity markets which are also adversely affecting this process. Notwithstanding the foregoing, the Company plans to file the Report no later than June 15, 2020 (which is 45 days from the Report’s original filing deadline of April 30, 2020).
where did you read that, can`t find any reference on their
website.
Company plans to file the Report no later than June 15, 2020 (which is 45 days from the Report’s original filing deadline of April 30, 2020).
I continue to add slowly but surely here..
I have high hopes for this stock.. in a sector that is clearly in favour now, and with next tranche funding in hand and progress clearly attainable off the back, I'm hoping for a meaningful wake up of this s/p soon enough... not least as it seems at a very low level generally ( at anywhere in 20-25p range)
DYOR and good luck to all fellow holders
Standby your beds. 232000 delayed trade at 24.8448 which just popped up.
last night, 230k, after the bell, 60k in cash,
that`s confidence!
Harmonics
Quite a few possible ahrmonics on this https://invst.ly/qo5k8
The shares had a 76.4% Fibonacci retracement on reaching 20p
Retracement Sequence from intraday high 28.5p, low 17.5p
0% 28.5 Last Intraday high
23.6% 25.9p
38.2% 24.3
50% 23
61.8% 21.7
76.4% 20.1 Bounce from on the next stage
100% 17.5p last Intraday low
Chart
http://uk.advfn.com/p.php?pid=staticchart&s=L%5EMPH&width=500&height=300&p=1&t=1&dm=2&vol=0&cb=
Quite interesting
Could that news help today's trading ..........
A New York-listed company has joined the race to buy the remnants of the biotech empire amassed by Neil Woodford, the fallen star UK fund manager.
Sky News has learnt that Acacia Research Corporation is among a small number of parties which remain in discussions about acquiring the portfolio of stakes in companies such as Mereo BioPharma and Rutherford Cancer Centres.
The discussions have been taking place for some time, but remain tentative, industry sources said.
https://news.sky.com/story/us-fund-acacia-eyes-remnants-of-woodfords-biotech-empire-11980545
Larger trades are now appearing in the ticker, 50K, 19.9K and 10K
maybe soon ready for another lift on the share price
Already paying 25p offer now with 320K volume
already more volume than during the last 2 weeks
chart volume
http://uk.advfn.com/p.php?pid=staticchart&s=L%5EMPH&width=600&height=280&p=2&t=1&dm=2&vol=1&cb=
Something is going on just look at the buys!
GL.
From the start of the day is all buys, and last trades paying over the offer price
Riddler - what do you think we’ll see in the morning with the price?
Thanks trufflehound I have been researching that over the last week. I’m very impressed with their technology. I think it’s going to be a massive scuffle for shares in the morning, wouldn’t be surprised to see 5p plus after open. I’ve got my buy price so will see if I can get my order filled
No problem, if you`re looking for something different in bio/pharma
sector, give DMTR a look, interesting little company, just took a
position myself.
as usual DYOR.